Prosecution Insights
Last updated: May 29, 2026

Sun Pharmaceutical Industries, Ltd.

8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
5
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

6
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (6)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (50%)
0
Easy (0%)
4
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only3 (38%)
Double-patenting + other1 (12%)
No statute on record4 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
88% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
12% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BECKHARDT, LYNDSEY MARIE 1 28.2% +48.7%
SCOTLAND, REBECCA LYNN 1 0.0% +0.0%
KIDWELL, MICHELE M 1 63.9% +19.2%
MERCIER, MELISSA S 1 71.9% +5.9%
KOMATSU, LI N 1 59.5% +70.8%
DONOGHUE, BRITTNEY ERIN 1 59.8% +55.2%
NIEBAUER, RONALD T 1 41.4% +33.8%
SOROUSH, LAYLA 1 40.2% +43.6%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18683932 STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF BECKHARDT, LYNDSEY MARIE 70d
18683943 STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF SCOTLAND, REBECCA LYNN 70d

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18278583 DEXAMETHASONE FOR TREATMENT OF BLEPHARITIS KIDWELL, MICHELE M 156d overdue
18002478 LONG ACTING GLP-1/GIP DUAL AGONISTS NIEBAUER, RONALD T 125d overdue
18158767 METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP DONOGHUE, BRITTNEY ERIN 88d overdue
18249055 GLP-1/GIP DUAL AGONISTS KOMATSU, LI N 44d overdue
17443766 STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE SOROUSH, LAYLA 42d overdue
18683932 STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF BECKHARDT, LYNDSEY MARIE 70d

Top Art Units

Art UnitApps
1615 2
1658 2
1613 1
3781 1
1675 1
1622 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18683932 STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF BECKHARDT, LYNDSEY MARIE 1613 DPOther Non-Final OA 70d Pending Feb 15, 2024
18683943 STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF SCOTLAND, REBECCA LYNN 1615 §103 Final Rejection 70d Pending Feb 15, 2024
18278583 DEXAMETHASONE FOR TREATMENT OF BLEPHARITIS KIDWELL, MICHELE M 3781 §103 Non-Final OA 156d overdue Pending Aug 23, 2023
18317625 MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION OF QUETIAPINE MERCIER, MELISSA S 1615 Other Non-Final OA 104d overdue Pending May 15, 2023
18249055 GLP-1/GIP DUAL AGONISTS KOMATSU, LI N 1658 Other Final Rejection 44d overdue Pending Apr 13, 2023
18158767 METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP DONOGHUE, BRITTNEY ERIN 1675 §103 Non-Final OA 88d overdue Pending Jan 24, 2023
18002478 LONG ACTING GLP-1/GIP DUAL AGONISTS NIEBAUER, RONALD T 1658 Other Non-Final OA 125d overdue Pending Dec 19, 2022
17443766 STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE SOROUSH, LAYLA 1622 Other Final Rejection 42d overdue Pending Jul 27, 2021

Managing Sun Pharmaceutical Industries, Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month